» Articles » PMID: 2252337

Serotonin and Migraine

Overview
Specialty Science
Date 1990 Jan 1
PMID 2252337
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Migraine has long been considered as a "vascular headache" but clearly neurological mechanisms are involved. The pathophysiology appears to somehow involve serotonin, both peripherally and centrally, but its involvement may be just epiphenomenal. Adding to the enigma it is apparent that many of the presently available drugs for the treatment of migraine interact in one way or another with serotonin receptors. However, they tend to have a number of other unrelated actions and they are only of limited clinical value. Interestingly a promising new drug for the treatment of the acute attack, sumatriptan, has a very selective action as an agonist at a specific 5-HT1-like receptor sub-type, mediating vasoconstriction, which is localized on cranial blood vessels. Its action may, or may not, be independent of any involvement of serotonin in the genesis of migraine. Hopefully though, current attempts to determine sumatriptan's mechanism of action will shed further light on the pathology of migraine itself and the putative involvement of serotonin.

Citing Articles

Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database.

Liu W, Hu H, Li C, Shi Q, Liu C, Liu A J Headache Pain. 2024; 25(1):206.

PMID: 39587512 PMC: 11587596. DOI: 10.1186/s10194-024-01913-0.


A role of NLRP3 and MMP9 in migraine progression: a systematic review of translational study.

Rushendran R, Singh A, Singh S, Chitra V, Ilango K Front Neurol. 2024; 15:1307319.

PMID: 38836002 PMC: 11148868. DOI: 10.3389/fneur.2024.1307319.


New characterization of dihydroergotamine receptor pharmacology in the context of migraine: utilization of a β-arrestin recruitment assay.

McConnachie L, Goadsby P, Vann R, Ray S, Shrewsbury S, Aurora S Front Neurol. 2023; 14:1282846.

PMID: 38073648 PMC: 10703426. DOI: 10.3389/fneur.2023.1282846.


The 5-HT receptor as the target of ditans in migraine - from bench to bedside.

Mitsikostas D, Waeber C, Sanchez-Del-Rio M, Raffaelli B, Ashina H, Brink A Nat Rev Neurol. 2023; 19(8):489-505.

PMID: 37438431 DOI: 10.1038/s41582-023-00842-x.


Headache: Treatment update.

Ogunlaja O, Goadsby P eNeurologicalSci. 2023; 29:100420.

PMID: 36636337 PMC: 9830470. DOI: 10.1016/j.ensci.2022.100420.